NanoString to Release Second Quarter 2019 Financial Results and Host Conference Call on Wednesday, July 31, 2019
July 10 2019 - 6:00AM
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life
science tools for translational research and molecular diagnostic
products, today announced that the Company will release second
quarter 2019 financial results after the close of trading on
Wednesday, July 31, 2019. Company management will host a conference
call beginning at 4:30pm ET to discuss those results and provide a
business update.
Individuals interested in listening to the
conference call may do so by dialing (888) 793-9492 for domestic
callers, or (734) 385-2643 for international callers. Please
reference Conference ID: 5182286. To listen to a live webcast,
please visit the investor relations section of the company’s
website at nanostring.com.
A replay of the call will be available beginning
July 31, 2019 at 7:30pm ET through midnight on August 7, 2019. To
access the replay, dial (855) 859-2056 or (404) 537-3406 and
reference Conference ID: 5182286. The webcast will also be
available on the Company’s website for one year following the
completion of the call.
About NanoString Technologies,
Inc.
NanoString Technologies is a leading provider of
life science tools for translational research and molecular
diagnostic products. The company's nCounter® Analysis System is
used in life sciences research and has been cited in more than
2,600 peer-reviewed publications. The nCounter Analysis System
offers a cost-effective way to easily profile the expression of
hundreds of genes, proteins, miRNAs, or copy number variations,
simultaneously with high sensitivity and precision, facilitating a
wide variety of basic research and translational medicine
applications, including biomarker discovery and validation. The
company’s GeoMx™ Digital Spatial Profiler enables
highly-multiplexed spatial profiling of RNA and protein targets in
a variety of sample types, including FFPE tissue
sections. The company's technology is also being used
in diagnostics. The Prosigna® Breast Cancer Prognostic Gene
Signature Assay together with the nCounter Dx Analysis System is
FDA 510(k) cleared for use as a prognostic indicator for distant
recurrence of breast cancer.
For more information, please visit
www.nanostring.com.
Contact:
Doug FarrellVice President, Investor Relations & Corporate
Communicationsdfarrell@nanostring.comPhone: 206-602-1768
NanoString Technologies (NASDAQ:NSTG)
Historical Stock Chart
From Aug 2024 to Sep 2024
NanoString Technologies (NASDAQ:NSTG)
Historical Stock Chart
From Sep 2023 to Sep 2024